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Abstract
Background: the addition of oligosaccharides to infant formula has been shown to mimic some of the beneficial effects of
human milk. The aim of the study was to assess the tolerance and safety of a formula containing an innovative mixture of
oligosaccharides in early infancy.
Methodology/Principal Findings: this study was performed as a multi-center, randomized, double-blind, placebo-
controlled trial including healthy term infants. Infants were recruited before the age of 8 weeks, either having started with
formula feeding or being fully breast-fed (breastfeeding group). Formula-fed infants were randomized to feeding with a
regular formula containing a mixture of neutral oligosaccharides and pectin-derived acidic oligosaccharides (prebiotic
formula group) or regular formula without oligosaccharides (control formula group). Growth, tolerance and adverse events
were assessed at 8, 16, 24 and 52 weeks of age. The prebiotic and control groups showed similar mean weight, length and
head circumference, skin fold thicknesses, arm circumference gains and stool frequency at each study point. As far as the
anthropometric parameters are concerned, the prebiotic group and the control group did not attain the values shown by
the breastfeeding group at any study point. The skin fold thicknesses assessed in the breastfeeding group at 8 weeks were
strikingly larger than those in formula fed infants, whereas at 52 weeks were strikingly smaller. The stool consistency in the
prebiotic group was softer than in the control group at 8, 16 and 24 weeks (p,0.001) and closer to that of the breastfeeding
group. There was no difference in the incidence of adverse events between the two formula groups.
Conclusions: our findings demonstrate the tolerability and the long term safety of a formula containing an innovative
mixture of oligosaccharides in a large cohort of healthy infants.
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Citation: Piemontese P, Giannı ` ML, Braegger CP, Chirico G, Gru ¨ber C, et al. (2011) Tolerance and Safety Evaluation in a Large Cohort of Healthy Infants Fed an
Innovative Prebiotic Formula: A Randomized Controlled Trial. PLoS ONE 6(11): e28010. doi:10.1371/journal.pone.0028010
Editor: Zulfiqar A. Bhutta, Aga Khan University, Pakistan
Received June 7, 2011; Accepted October 30, 2011; Published November 30, 2011
Copyright:  2011 Piemontese et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by Danone research, Friedrichsdorf Germany. The role of the funder has been to supply the study formulas and facilitate the
data collection and data analysis.
Competing Interests: CG and GC receive research support from Danone. CB has consultant arrangements and receives research support from Danone. JR is on
the advisory board for Numico and receives research support from MIPS. JJ and GB are employed by Danone Research - Centre for Specialised Nutrition. This does
not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials. The rest of the authors have declared that they have no conflict of
interest.
* E-mail: paola.roggero@unimi.it
Introduction
Several of the health benefits related to breastfeeding have been
ascribed to oligosaccharides that modulate the development of a
typical gut microbiota [1]. Indeed, they play a major role in
generating a microbiota characterized predominantly by the
presence of bifidobacteria and lactobacilli [2]. On the contrary,
the microbiota of formula-fed infants compromises more Bacteroi-
des, Staphylococci, Escherichia Coli and Clostridia [3]. There is
evidence that the development of bifidobacteria predominant
microbiota may favour a decreased incidence of infections, allergies
and gastrointestinal symptoms as seen in breast-fed infants
compared with formula-fed infants [4]. On the basis of the available
data, for infants who are not breastfed, it seems reasonable to
supplement infant formulas with oligosaccharides in order to
develop intestinal microbiota similar to that of breastfed infants.
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e28010In human milk 80–85% of the oligosaccharides are neutral and
15–20% are acidic. A specific mixture of neutral oligosaccharides
of non-milk origin has been developed to mimic the neutral
oligosaccharides fraction of human milk, namely, short chain
galacto-oligosaccharides which derived from enzymatic conversion
of lactose and long chain fructo-oligosaccharides from chicory
derived inulin [5]. The human acidic-oligosaccharides composi-
tion is different from the composition of acidic-oligosaccharides
used to supplement infant formula. The latter are derived from the
enzymatic cleavage of citrus pectin acidic-oligosaccharides [6].
The combination of short chain galacto-oligosaccharides/long
chain fructo-oligosaccharides with pectin acidic-oligosaccharides
may favour the development of a bifidogenic microbiota, decrease
the growth of pathogens in the intestine, have a positive effect on
the mucus layer of the gastrointestinal tract, and may stimulate the
maturation of the immune system [6–9].
To our knowledge there are no large and longitudinal trials on
the gastrointestinal tolerance and long term safety of an infant
formula supplemented with the mixture comprehensive of pectin
acidic-oligosaccharides in addition to the well known neutral
prebiotics (short chain galacto-oligosaccharides/long chain fructo-
oligosaccharides [10].
In this study, we aimed to evaluate the tolerance and safety of
an infant formula supplemented with a mixture of short chain
galacto-oligosaccharides, long chain fructo-oligosaccharides and
pectin acidic-oligosaccharides, in healthy infants during the first
year of life by investigating effects on growth, gastrointestinal
tolerance and stool consistency and by identifying any adverse
effects.
Materials and Methods
The protocol of this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics Statement
Written informed consent was obtained from all parents before
randomization. All participating centers obtained approval of their
local Ethical Review Board.
Study design
This study was performed as a double blind, placebo-controlled,
randomized prospective nutritional intervention study. The study
was designed to determine whether a formula supplemented with a
specific mixture of neutral and acidic oligosaccharides reduces the
incidence of fever episodes and the occurrence of atopic dermatitis
in healthy term born infants during the first year of life [7–8]. The
study was registered in the German Clinical Trials Register
(registration code DRKS 00000201).
Participating centres
Participating study centres were the Beatrix Children’s Hospital
in Groningen, the Netherlands; the Schwarzach Hospital in
Schwarzach, Austria; the University Children’s Hospital in Zu ¨rich,
Switzerland; the Mangiagalli Hospital in Milan, Italy; the
Macedonio Melloni Hospital in Milan, Italy; the Charite ´-
Universita ¨tsmedizin Berlin in Berlin, Germany; and the Spedali
Civili Hospital in Brescia, Italy.
Subjects
Parents of infants less than 8 weeks of age from the region of the
participating centres were informed of the study and asked to
contact the research centres if interested in participating.
Inclusion criteria
We included healthy, term infants (gestational age 37 to 42
weeks), with a normal birth weight (.p10 and ,p90 for gestational
age according to locally applicable growth charts), aged up to 8
weeks when entering the study, without a positive family history of
allergic disease (hay fever, asthma or atopic dermatitis) and without
a metabolic disorder requiring a special diet.
With regard to the breast fed group additional inclusion criteria
were the intention of mothers to exclusively breastfeed their infants
at least for 4 months and being exclusively breastfed at time of
enrollment.
Exclusion criteria
Exclusion criteria included mothers suffering from hepatitis B,
HIV or Group B streptococcal infection during pregnancy;
mothers taking antibiotics during breastfeeding; infants with
known congenital or postnatal diseases which could interfere with
the study and any pre-study feeding of the infants which could
interfere with the study.
Procedures
Mothers were encouraged to breastfeed their infant for at least 4
months and preferably 6 months.
Enrollment and randomization occurred at the same time and
were performed within 8 weeks after delivery (table 1).
Only if mothers could not or intended not to exclusively
breastfeed their infants, the local study team asked mothers for
their consent to participate in the study and to be randomized to
one of the two formula groups.
In the case of a switch form breastfeeding to formula feeding
that took place due to insufficient breastfeeding within eight weeks
after delivery, mothers were also asked for their consent to
participate in the study and to be randomized to one of the two
formula groups.
If infants continued to assume both breast milk and at least one
bottle of formula after the 8th week of age, they were allocated to
the mixed feeding group.
Infants of mothers who indicated that they would exclusively
breastfeed were included in the breastfeeding group. This group
served as the non-randomized reference group.
Randomisation was performed stratified according to study
centre. Time balanced randomisation was performed with the
software RANCODE with a random permuted block size of 4.
Only the hospital pharmacist had a copy of the randomisation list
with the actual treatment allocation. Both the investigators and the
infants’ parents were blind to the group allocation. The tins and
the milk powder looked and smelled identical.
Infants randomized to the prebiotics group received a regular
non-hydrolysed cow’s milk based formula (proteins 1,3 g/100 ml,
whey/casein 60/40) complying with the EC directive on infant
formulae and follow-on formulae (proteins 1,4 g/100 ml, whey/
casein 50/50), to which a specific mixture of neutral short chain
galacto-oligosaccharides and long chain fructo-oligosaccharides,
ratio 9:1 (IMMUNOFORTISH, Nutricia Cuijk BV, Cuijk, The
Netherlands; 85 wt%) and specific pectin acidic-oligosaccharides
(15 wt%), was added.
The total amount of oligosaccharides was 8 g/L with 6.8 g/L
neutral and 1.2 g/L pectin acidic-oligosaccharides. Infants random-
ized to the control group received a similar regular non-hydrolysed
cows milk based formula without added oligosaccharides.
Study formulas were started straightaway after randomization
(table 1). For both groups starter formula was provided during the
first six months of life, thereafter follow-on formula was provided
to all formula fed infants up to one year of age. Infants randomized
Safety of an Innovative Prebiotic Formula
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the follow-on formula. All participating mothers from either
exclusive breast feeding or formula feeding were advised not to
introduce complementary foods before the age of 4 months. All
study formulas were manufactured and provided by Danone
Research (at the time the study was conducted NUMICO), Cuijk,
The Netherlands.
Observation period
The observation period was until the age of one year. Parents
were contacted every two weeks (after the age of 16 weeks every
four weeks), either by home visits, clinic visit, or phone calls.
During these interviews data about the onset of gastrointestinal
symptoms or any other symptoms as well as prescribed drugs were
collected. To help accuracy of recall, parents kept a symptom and
therapy diary.
At study entry, 2 (+/2 1 week), 4 (+/2 1 week), 6 (+/2 1 week),
and 12 (+/2 2 weeks) months of life, infants were clinically
examined and underwent assessment of anthropometric measure-
ments at the study centers and their homes.
Outcomes
Anthropometric measurements. The infants’ anthropometric
measurements (body weight, length, head circumference, mid-
upper arm circumference, triceps and subscapular skinfolds)
were obtained using standardized techniques [11]. The naked
infants were weighed on an electronic scale accurate to 0.5 g.
Recumbent length was measured on a Harpenden stadiometer
to the nearest 1 mm. The head circumference was measured
using a non-stretch measuring tape to the nearest 1 mm. As an
indicator of body composition (regional fat and fat-free tissue),
mid-upper arm circumference was measured with a non-stretch
tape at the midpoint between the acromium and olecranon to
the nearest 1 mm; triceps and subscapular skinfold thickness
were examined by means of a Holtain skinfold caliper calibrated
to 0.2 mm [12].
Skinfold thickness was assessed three times and the mean of
three readings was taken. The measurements were performed by
experienced personnel. Actual chronological decimal age was used
to calculate the standardized anthropometric indices (z scores)
[13].
The growth rate was calculated as a change in body weight from
weight at study inclusion divided by the time interval from
enrolment to the assessments at week 16.
Gastrointestinal tolerance parameters. Indicators of
gastrointestinal tolerance were collected at each study point
using diaries and included the following: regurgitation/reflux
[spitting up (mild), posseting (moderate), vomiting (severe)],
Table 1. Baseline characteristics.
PG CG BG
N=414 N=416 N=300
Age at enrollment/randomization (days) 30 (20–42) 32 (21–45) 50 (36–54)
Birth weight (grams) 3277 (2965–3610) 3320 (2930–3625) 3438 (3110–3678)
Gestational age (completed weeks) 39 (38–40) 39 (38–40) 40 (39–40)
Boys 220 (53%) 200 (48%) 134 (45%)
White race 378 (91%) 392 (94%) 287 (96%)
Vaginal delivery 261 (63%) 272 (65%) 247 (82%)
Caesarean Section (incl. Elective) 153 (37%) 144 (35%) 53 (18%)
Rooms in household (not kitchen/bathroom) 3 (3–4) 3 (3–4) 4 (3–5)
Number of children in household 2 (1–2) 2 (1–2) 2 (1–2)
Single parent family 25 (6%) 23 (6%) 17 (6%)
Furry pets in household 133 (32%) 150 (36%) 95 (32%)
Smoking mother 79 (19%) 81 (19%) 21 (7%)
Smoking father 142 (35%) 163 (40%) 81 (27%)
Education level of the mother
primary and secondary school 206 (50%) 208 (50%) 115 (38%)
some university education/some postsecondary education/
technical or trade qualification
138 (33%) 119 (29%) 107 (36%)
completed university degree 69 (17%) 89 (21%) 78 (26%)
Mother employed 252 (61%) 269 (65%) 207 (69%)
Education level of the father
primary and secondary school 184 (46%) 188 (46%) 101 (34%)
some university education/some postsecondary education/
technical or trade qualification
142 (35%) 127 (31%) 113 (38%)
completed university degree 77 (19%) 95 (23%) 85 (28%)
Father employed 369 (92%) 377 (92%) 283 (95%)
For continuous variables: median (25–75 percentile) values.
For categorical data: percentages.
PG=prebiotics group; CG=control group; BG=breastfeeding group.
doi:10.1371/journal.pone.0028010.t001
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rectum), cramps (unpleasant sensation caused by abdominal
contraction), colic (intermittent attacks of abdominal pain when
the baby screamed and drew up his/her legs but was well between
episodes), nappy rash (redness of the skin confined to the area
covered by the nappy), daily frequency of stool passage and stool
consistency (on a five-point scale: 1= watery, 2=loose, 3=soft,
4= formed, 5=hard).
Adverse events (AEs). AEs were assessed based on inquires
to the parents and on their daily records. All AEs were recorded
in adverse event forms and were evaluated by the investigator for
causality for the relationship to the study feeding and for severity.
An AE was defined as any event, that was not consistent with the
information provided in the consent form or could reasonably be
expected to accompany the natural history and progression of the
subject’s condition throughout the study. AEs were considered as
serious (SAEs) if they were fatal or life-threatening, required
hospitalization or surgical intervention, resulted in persistent or
significant disability/incapacity or were considered to be
medically relevant by the investigator. All other AEs were
categorized as non-serious. AEs were assessed according to body
system.
Power Calculation
The power of the study was calculated considering the infectious
diseases as primary outcome. Starting with 500 formula infants per
group, it was assumed that about 35% will be lost for the per-
protocol analysis due to continuation of breastfeeding beyond the
second month of life and further about 15% due to different
dropout/withdrawal reasons so that 250 infants per formula group
fully completing the study should be achieved. With those 250
formula infants per group completing the study without violation
of the protocol a reduction of the mean number of febrile episodes
by 1 which is considered as clinically relevant reduction from 4.5
infection episodes to 3.5 (SD 3.5 episodes) [home care, group care
(2–6 children), and day care (.6 children)], compared to placebo
can be proven with 93% power in an one-sided unpaired t-test or
89% in a two-sided unpaired t-test [14].
Statistical Methods
All statistical analyses were performed with SASH, Version 9
(SAS Institute,Cary, NC). A p-value of ,0.05 was assumed to
indicate statistical significance in all tests. All analyses were
performed with stratification per centre, unless numbers were too
small or a centre effect was not expected.
Figure 1. Trial profile.
doi:10.1371/journal.pone.0028010.g001
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analysis. All infants who had been randomized in the prebiotics
group or the control group were included in the analysis. As
breastfeeding group infants were not randomized, no statistical
analysis was performed to compare the breastfeeding group with
any of the formula feeding groups.
The size of both groups had been calculated for the primary
endpoint of the trial.
Continuous variables were reported as mean and standard
deviation (SD) or mean and standard error of mean (SEM) or
median and interquartile ranges. Categorical variables were
reported as numbers or percentages. They were compared using
stratified linear regression, Cochran-Mantel-Haenszel or non-
parametric stratified Wilcoxon tests, as appropriate for continuous
and categorical variables.
Z-scores for weight, length and head circumference were
calculated with the EUROGROWTH software (http://www.
euro-growth.org/).
Repeated measures linear and logistic regression, using center as
a random effect, were used to compare anthropometric and
gastrointestinal discomfort symptoms. The stool consistency data
was analyzed using a Baseline Category Logit Model (BCL).
Compiled frequency tables for adverse events, according to the
body system, were based on number of infants experiencing the
(serious) adverse event. Group differences were evaluated using
Fisher’s exact test.
Results
Study population
From July 2005 to December 2006 a total of 1187 infants were
screened. Fifty-seven of these infants were not enrolled as they did
not meet the inclusion criteria. 1130 infants participated and
were randomized into one of the 2 study groups or were fully
breastfed and included in the breastfeeding group. The intention
to treat population comprised 414 infants in the prebiotics group,
416 infants in the control group. The trial profile is shown in
Figure 1. During the observation period 129 patients (11%)
dropped out (prebiotics group, n=53; control group, n=42;
breastfeeding group, n=34). With regard to the breastfeeding
group, 243 infants completed the study protocol as 23 infants
switched to mixed feeding. Twenty-seven percent of the recruited
infants were fully breastfed for at least 4 months. The baseline
characteristics and demographics of the infants are summarized
per group in Table 1. No difference between the two formula
groups was found. The observation period lasted one year and
ended in December 2007.
Anthropometric measurements
There was no difference in the mean body weight, length and
head circumference values between the two formula groups at any
assessed time point. From enrollment to 16 weeks, the mean growth
ratewas30.9 g/daywith SEof0.53and29.9 g/daywith SEof0.53
for the prebiotics group and for the control group, respectively.
As far as the z-scores for weight, length and head circumference
are concerned, the prebiotics group and control group did not
reach the range of breastfeeding group at any study point (Table 2).
In the 6–12 month interval growth indices progressively declined
for breastfeeding group.
No statistical significant differences were found in the skin fold
thicknesses (Figure 2, 3) and in the arm circumference values
(Table 3) between the two formula groups. The skin fold
thicknesses assessed in the breastfeeding group at 8 weeks were
strikingly larger than those in formula fed infants, whereas at 52
weeks were strikingly smaller.
Gastrointestinal tolerance
Table 4 shows data related to the gastrointestinal symptoms
during the treatment period. No difference in the incidence of any
gastrointestinal symptom was detected between the two formula
groups. Both formula groups showed a similar daily stool frequency
at each study point. The incidence of the gastrointestinal symptoms
and the daily stool frequency in the prebiotics group and control
group partly differs fromthe one ofbreastfeedinggroup at any study
point. No significant difference in the occurrence of nappy rash
(data not shown) was found between the two formula groups. The
number of spitting episodes within the first 24 weeks of age in the
formula groups partly differs from the one of breastfeeding group
infants, whereas the frequency of vomiting in the two formula
groups was similar to that in the breastfeeding group. At 8 weeks the
occurrence of colic in the prebiotics group and control group partly
differs from the one of breastfeeding group. The stool frequency in
the prebiotics group and control group partly differs from the one of
breastfeeding group at any study point.
The stool consistency was significantly lower in the prebiotics
group at 8, 16 and 24 weeks as compared to the control group
(p,0.001) and closer to the breastfeeding group (Figure 4). As it
can be seen in table 4 the lower stool consistency score in the
prebiotics group compared to the control group was associated
with a higher number of loose and soft stools and a smaller
number of formed and hard stools
Adverse events
In total, 640 AEs occurred in 431 infants. Of these, 112 AEs
occurring in 110 infants were assessed as serious. Documented
reasons for all AEs were mostly illnesses which are common during
the first year of life (i.e. otitis media, bronchitis, gastroenteritis,
upper respiratory tract infection, varicella, bronchiolitis, pharyngi-
tis, urinary tract infection). There were no differences in the
incidence of AEs (prebiotics group 31% vs. control group 30%;
p.0.05) and SAEs (prebiotics group 10,6% vs. control group 9,4%)
between the groups. SAEs occurred in 9,3% of breast fed infants.
Table 2. Weight, length and head circumference for-age z-
scores.
Weight Length
Head
circumference
8 Weeks PG 20,02697 (0.050) 0,04662 (0.054) 20,0206 (0.048)
CG 20,00831 (0.050) 0,03694 (0.054) 20,05479 (0.048)
BG 0,2682 (0.060) 0,296 (0.065) 0,1318 (0.057)
16 Weeks PG 20,03664 (0.047) 0,08803 (0.048) 20,03896 (0.043)
CG 20,00767 (0.047) 0,07352 (0.047) 20,06434 (0.043)
BG 0,1512 (0.056) 0,2219 (0.057) 0,05057 (0.052)
24 Weeks PG 20,04630 (0.045) 0,1294 (0.044) 20,05732 (0.041)
CG 20,00704 (0.045) 0,1101 (0.043) 20,0739 (0.040)
BG 0,03428 (0.047) 0,1477 (0.045) 20,03062 (0.045)
52 Weeks PG 20,08015 (0.052) 0,2744 (0.057) 20,1216 (0.050)
CG 20,0048 (0.051) 0,2381 (0.056) 20,1074 (0.049)
BG 20,375 (0.062) 20,112 (0.068) 20,3148 (0.059)
Data are presented as mean (standard error of mean).
PG=prebiotics group; CG=control group; BG=breastfeeding group.
doi:10.1371/journal.pone.0028010.t002
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linear and logistic regression, using centre as a random effect PG=prebiotics group; CG=control group; BG=breastfeeding group.
doi:10.1371/journal.pone.0028010.g002
Figure 3. Mean (SE) triceps skinfold thickness values. P.0.05 for comparisons between PG and CG, resulting from repeated measures linear
and logistic regression, using centre as a random effect PG=prebiotics group; CG=control group; BG=breastfeeding group.
doi:10.1371/journal.pone.0028010.g003
Safety of an Innovative Prebiotic Formula
PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e28010Discussion
To our knowledge, the present study is the largest trial
investigating the effect of supplementation with an innovative
mixture of short chain galacto-oligosaccharides/long chain fructo-
oligosaccharides/pectin acidic-oligosaccharides on gastrointestinal
tolerance and safety in full-term infants over a period of one year.
The results of this study clearly demonstrated that this prebiotic
mixture containing not only the neutral oligosaccharides (short
chain galacto-oligosaccharides, long chain fructo-oligosaccharides)
but also the acidic oligosaccharides pectin acidic-oligosaccharides
was safe and well tolerated. These results supplement the recently
published efficacy data on the incidence of fever episodes and the
occurrence of atopic dermatitis in healthy term born infants during
the first year of life [7–8].
In order to assess whether the prebiotic formula is tolerated and
allows a growth as found in breastfed infants, we would have had
to compare the formula groups with the breastfeeding group.
However, it is impossible to randomize infants to either
breastfeeding or a formula. As a result, groups are not comparable
and therefore we made no statistical comparisons.
The infants that received the supplemented formula showed no
significant changes in z-scores for weight, length and head
circumference values during the first year of life and in the rate
of weight gain until the age of four months as compared to the
infants fed the control formula. Furthermore, all infants exhibited
linear, ponderal and head circumference growth rates within the
normal range as compared with the standardized European
growth references [11].
In order to exclude the possibility that the absence of any
significant variation in the rate of weight gain could be due to an
inadequate sample size, we performed a power calculation to
detect a difference in weight gain of 3 g/day over a 3 to 4 month
period, which is considered to be nutritionally significant [15], for
prebiotics group versus control group in the intention-to-treat
population, which was 87% (assessed by a two-sided t-test using an
alpha of 5%).
As far as the breastfed infants are concerned, we found higher
rates of growth increments in the first six months of life than the
formula fed subjects. This finding is in agreement with results from
previous studies where breastfed infants presented higher growth
rate during the first months of life compared with formula-fed
infants [16–18].
Our results are consistent with the observation that infants fed
formula supplemented with different combinations of prebiotics
achieve a growth within the normal range [6,19,20].
The effect of acidic-oligosaccharides and galacto-oligosaccha-
rides/fructo-oligosaccharides/acidic-oligosaccharides on safety as
well as tolerance was previously investigated only by Fanaro et al
[6] by means of an explorative study. The authors reported that
there was no difference in growth and gastrointestinal tolerance
between groups. Our data confirm the results of this study
conducted in a small sample of infants (n=46) for a relatively short
period of six weeks.
With regard to gastrointestinal tolerance, the occurrence of
gastrointestinal symptoms was throughout the study similar in the
prebiotics group and control group. In agreement with our
findings, previous studies have reported that prebiotic supplemen-
tation does not affect gastrointestinal symptoms except stool
consistency [19–22]. In our study stool consistency scores in
Table 3. Arm circumference values at each study point.
Weeks
Arm circumference
(cm)
PG CG BG
8 12.64 (0.06) 12.67 (0.06) 12.67 (0.07)
16 13.82 (0.05) 13.83 (0.05) 13.72 (0.07)
24 14.71 (0.06) 14.71 (0.06) 14.52 (0.07)
52 15.57 (0.06) 15.62 (0.06) 15.29 (0.08)
Data are presented as mean (standard error of mean) P.0.05 for comparisons
between PG and CG, resulting from repeated measures linear and logistic
regression, using center as a random effect.
PG=prebiotics group; CG=control group; BG=breastfeeding group.
doi:10.1371/journal.pone.0028010.t003
Table 4. Episodes of gastrointestinal symptoms and daily stool frequency.
Spitting n(%) Posseting n(%) Vomiting n(%) Colics n(%) Flatulence n(%) Cramps n(%)
Daily stool
frequency mean
(SD)
8 Weeks PG 216 (56.3) 158 (41.1) 35 (9.1) 112 (27.7) 230 (56.9) 130 (32.2) 1.66 (1.282)
CG 206 (54.4) 176 (46.4) 39 (10.3) 109 (26.4) 233 (56.4) 131 (31.7) 1.68 (1.166)
BG 171 (67.6) 101 (39.9) 31 (12.3) 61 (21.5) 172 (60.4) 96 (33.7) 2.76 (1.945)
16 Weeks PG 195 (51.5) 146 (38.5) 27 (7.1) 42 (10.9) 131 (33.9) 43 (11.1) 1.28 (0.750)
CG 186 (49.1) 158 (41.7) 27 (7.1) 38 (9.7) 145 (36.9) 48 (12.2) 1.26 (0.841)
BG 180 (65.7) 115 (42.0) 28 (10.2) 20 (7.2) 103 (36.9) 27 (9.7) 1.84 (1.280)
24 Weeks PG 181 (47.6) 133 (35.0) 26 (6.8) 10 (2.6) 90 (23.6) 10 (2.6) 1.44 (0.743)
CG 174 (45.8) 121 (31.8) 29 (7.6) 10 (2.6) 81 (21.0) 14 (3.6) 1.41 (0.706)
BG 169 (62.1) 100 (36.8) 31 (11.4) 13 (4.7) 67 (24.4) 11 (4.0) 1.52 (0.911)
52 Weeks PG 33 (9.6) 18 (5.2) 12 (3.5) 1 (0.3) 51 (14.2) 1 (0.3) 1.73 (0.779)
CG 30 (8.4) 23 (6.4) 11 (3.1) 2 (0.5) 38 (10.2) 4 (1.1) 1.69 (0.748)
BG 45 (17.4) 22 (8.5) 12 (4.6) 1 (0.4) 21 (7.9) 3 (1.1) 1.75 (0.869)
P.0.05 for all comparisons between PG and CG, resulting from repeated measures linear and logistic regression, using center as a random effect.
PG=prebiotics group; CG=control group; BG=breastfeeding group.
doi:10.1371/journal.pone.0028010.t004
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significantly lower than those in the control group at 8, 16, 24
weeks, and closer to those presented by breastfed infants. As seen
in table 4 the lower stool consistency score in the prebiotics group
compared to the control group was based on a higher number of
loose and soft stools and a smaller number of formed and hard
stools. This latter finding is clinically relevant, as in daily practice
mothers of formula-fed infants frequently complain about high
stool consistency which may cause discomfort. In addition,
several studies have demonstrated that formula supplemented
with prebiotics promotes the development of a stool consistency
similar to those of breastfed infants [19–21]. Indeed, Moro et al
[19] showed that short chain galacto-oligosaccharides and long
chain fructo-oligosaccharides ratio 9:1 fed to term infants reach
the colon and interact quantitatively with the intestinal
microbiota, imitating the fate of oligosaccharides found in human
milk.
The stool frequency rate found through the study was similar
in the prebiotics group and control group and it was slightly
lower compared to that of breastfeeding group only in the first
two months of life. Although previous studies have demonstrat-
ed that short chain galacto-oligosaccharides/long chain fructo-
oligosaccharides (9:1) determine a slight increase in stool
frequency [19,21], the tendency for increased stool frequency
reported in infants fed prebiotics may not be of clinical
relevance as these frequencies are in the normal range for
healthy infants.
Drop-out rates, reasons for dropping out and the incidence of
serious adverse events were similar in both the prebiotics group
and control group demonstrating that the prebiotic formula was
safe and well tolerated.
Our results demonstrate that a formula supplemented with this
innovative mixture of neutral and acidic oligosaccharides is well
tolerated and safe in healthy full-term infants during the first year
of life.
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